title: B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC/BCL2 double-hit lymphomas.
abstract: Large B-cell lymphomas with IGH@BCL2 and MYC rearrangement, known as double-hit lymphoma (DHL), are clinically aggressive neoplasms with a poor prognosis. Some large B-cell lymphomas have concurrent abnormalities of MYC and BCL2 other than coexistent translocations. Little is known about patients with these lymphomas designated here as atypical DHL. We studied 40 patients of atypical DHL including 21 men and 19 women, with a median age of 60 years. Nine (23%) patients had a history of B-cell non-Hodgkin lymphoma. There were 30 diffuse large B-cell lymphoma (DLBCL), 7 B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma, and 3 DLBCL with coexistent follicular lymphoma. CD10, BCL2, and MYC were expressed in 28/39 (72%), 33/35 (94%), and 14/20 (70%) cases, respectively. Patients were treated with standard (n=14) or more aggressive chemotherapy regimens (n=17). We compared the atypical DHL group with 76 patients with DHLand 35 patients with DLBCL lacking MYC and BCL2 abnormalities. The clinicopathologic features and therapies were similar between patients with atypical and typical DHL. The overall survival of patients with atypical double-hit lymphoma was similar to that of patients with double-hit lymphoma (P=0.47) and significantly worse than that of patients with DLBCL with normal MYC and BCL2 (P=0.02). There were some minor differences. Cases of atypical double-hit lymphoma more often have DLBCL morphology (P<0.01), less frequently expressed CD10 (P<0.01), and patients less often had an elevated serum lactate dehydrogenase level (P=0.01). In aggregate, these results support expanding the category of MYC/BCL2 DHL to include large B-cell lymphomas with coexistent MYC and BCL2 abnormalities other than concurrent translocations.
authors.affiliation: Division of Hematopathology, Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Vanderbilt University School of Medicine, Nashville, TN, USA.
authors.forename: Shaoying
authors.initials: S
authors.lastname: Li
authors.affiliation: Division of Hematopathology, Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Vanderbilt University School of Medicine, Nashville, TN, USA.
authors.forename: Adam C
authors.initials: AC
authors.lastname: Seegmiller
authors.affiliation: Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Pei
authors.initials: P
authors.lastname: Lin
authors.affiliation: Division of Hematopathology, Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Vanderbilt University School of Medicine, Nashville, TN, USA.
authors.forename: Xuan J
authors.initials: XJ
authors.lastname: Wang
authors.affiliation: Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Roberto N
authors.initials: RN
authors.lastname: Miranda
authors.affiliation: Department of Pathology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
authors.forename: Sharathkumar
authors.initials: S
authors.lastname: Bhagavathi
authors.affiliation: Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: L Jeffrey
authors.initials: LJ
authors.lastname: Medeiros
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D005260:Female; D019254:Genes, bcl-2 / Q000235:genetics*; D016259:Genes, myc / Q000235:genetics*; D006801:Humans; D016130:Immunophenotyping; D017404:In Situ Hybridization, Fluorescence; D016393:Lymphoma, B-Cell / Q000235:genetics* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D015260:Neprilysin / Q000096:biosynthesis; D055815:Young Adult
chemical_list: D015260:Neprilysin
references.citation: Exp Cell Res. 1995 Apr;217(2):240-7
references.pmid: 7698223
references.citation: Histopathology. 2008 Aug;53(2):205-17
references.pmid: 18752503
references.citation: Haematologica. 2013 Oct;98(10):1554-62
references.pmid: 23716551
references.citation: Haematologica. 2007 Oct;92(10):1297-301
references.pmid: 18024366
references.citation: Leukemia. 2012 Sep;26(9):2103-13
references.pmid: 22437443
references.citation: Mol Cancer. 2010 Apr 30;9:97
references.pmid: 20433747
references.citation: Blood Cells Mol Dis. 2010 Dec 15;45(4):317-23
references.pmid: 20817505
references.citation: Am J Surg Pathol. 2005 Aug;29(8):1067-73
references.pmid: 16006802
references.citation: Br J Haematol. 2011 Oct;155(2):274-7
references.pmid: 21488860
references.citation: Blood. 2011 Feb 24;117(8):2319-31
references.pmid: 21119107
references.citation: Blood. 2009 Sep 10;114(11):2273-9
references.pmid: 19597184
references.citation: Nat Genet. 2008 Jan;40(1):43-50
references.pmid: 18066065
references.citation: Am J Surg Pathol. 2010 Mar;34(3):327-40
references.pmid: 20118770
references.citation: J Clin Oncol. 1999 May;17(5):1558-67
references.pmid: 10334544
references.citation: Haematologica. 2013 Feb;98(2):255-63
references.pmid: 22929980
references.citation: Cell. 2012 Sep 28;151(1):68-79
references.pmid: 23021216
references.citation: Blood. 2011 Jun 9;117(23):6255-66
references.pmid: 21478429
references.citation: J Pathol. 2005 Jun;206(2):123-34
references.pmid: 15880597
references.citation: Zhonghua Bing Li Xue Za Zhi. 2007 Feb;36(2):84-9
references.pmid: 17493380
references.citation: Cancer Cell. 2012 Oct 16;22(4):506-523
references.pmid: 23079660
references.citation: Eur J Haematol. 2012 Jul;89(1):63-71
references.pmid: 22510149
references.citation: Blood. 2013 May 16;121(20):4021-31; quiz 4250
references.pmid: 23449635
references.citation: Adv Anat Pathol. 2013 Sep;20(5):315-26
references.pmid: 23939148
references.citation: J Clin Oncol. 2012 Oct 1;30(28):3460-7
references.pmid: 22665537
references.citation: Oncogene. 2013 Feb 21;32(8):1066-1072
references.pmid: 22484426
references.citation: Mod Pathol. 2012 Jan;25(1):145-56
references.pmid: 22002575
references.citation: Leuk Lymphoma. 2006 Sep;47(9):1885-93
references.pmid: 17065002
references.citation: Haematologica. 2007 Oct;92(10):1335-42
references.pmid: 18024371
references.citation: Leukemia. 2009 Apr;23(4):777-83
references.pmid: 19151788
references.citation: Br J Haematol. 2010 May;149(4):484-97
references.pmid: 20346013
references.citation: J Clin Oncol. 2012 Oct 1;30(28):3452-9
references.pmid: 22851565
references.citation: Haematologica. 2009 Jul;94(7):935-43
references.pmid: 19535347
references.citation: Blood. 2004 Jan 1;103(1):275-82
references.pmid: 14504078
references.citation: Mod Pathol. 2006 Jan;19(1):25-33
references.pmid: 16258503
references.citation: Blood. 1997 Aug 1;90(3):1168-74
references.pmid: 9242549
references.citation: Annu Rev Immunol. 2012;30:565-610
references.pmid: 22224767
references.citation: Genes Cancer. 2010 Jun;1(6):660-7
references.pmid: 21779463